Pharmacology · Endocrine Pharmacology

A 72-year-old woman with severe osteoporosis and two prior vertebral compression fractures is started on teriparatide. Its mechanism of action is:

  • A Inhibition of osteoclast-mediated bone resorption
  • B Stimulation of osteoblast-mediated bone formation
  • C Enhancement of intestinal calcium absorption
  • D Reduction of renal calcium excretion
Correct answer: B. Stimulation of osteoblast-mediated bone formation

Explanation

Teriparatide is recombinant parathyroid hormone (1-34) and is the only anabolic agent approved for osteoporosis. Intermittent PTH exposure stimulates osteoblast activity and new bone formation. Bisphosphonates and denosumab inhibit osteoclast-mediated resorption. While PTH can indirectly affect calcium handling, its therapeutic effect in osteoporosis is through bone formation.

Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.

Sponsored

Want to test yourself?

Create a free account for timed mock tests, mistake tracking, and FSRS spaced-repetition revision across 43,000+ MCQs.

Start free → Log in

More Endocrine Pharmacology MCQs

See all Endocrine Pharmacology MCQs →